Shattuck Labs, Inc. (STTK) has a MoatMap StockRank of 31/100 based on Quality (30/100), Value (34/100), and Momentum (54/100) factor scores. The current signal is SELL. An early-stage clinical biotech with high binary trial risk and no current revenues, failing all quality compounder and margin of safety criteria.
Shattuck Labs is a clinical-stage biotechnology company focused on developing novel immune-oncology and autoimmune disease therapies using its proprietary ADAPTIR™ platform. This platform engineers bifunctional fusion proteins designed to simultaneously deliver co-stimulatory and co-inhibitory signals, offering a differentiated approach to modulate the immune system. As a niche player, Shattuck aims to disrupt established treatment paradigms in areas of high unmet medical need.
| Price | $4.27 |
| Market Cap | $458M |
| P/E (Forward) | -9.38 |
| Price/Book | 3.79 |
| Return on Equity | -61.0% |
| Return on Invested Capital | -61.3% |
| Debt/Equity | 3.02 |
| Gross Margin | -297.8% |
| Operating Margin | -5258.3% |
| Free Cash Flow | $-22M |
Shattuck Labs, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).